, Volume 109, Issue 4, pp 466–472 | Cite as

Hyperthermia induced bym-trifluoromethylphenylpiperazine (TFMPP) orm-chlorophenylpiperazine (m-CPP) in heat-adapted rats

  • A. Kłodzińska
  • E. Chojnacka-Wójcik
Original Investigations


TFMPP andm-CPP, non-selective 5-HT agonists, administered in doses of 1–20 mg/kg evoked hyperthermia in rats at a high ambient temperature (28°C). The hyperthermic effect of TFMPP (10 mg/kg) orm-CPP (10 mg/kg) was dose-dependently antagonized by the 5-HT1c and 5-HT2 receptor antagonists mesulergine (0.5–4 mg/kg), ketanserin (0.6–2.5 mg/kg) and ritanserin (0.5–2 mg/kg) and by the non-selective 5-HT antagonist metergoline (0.5–1 mg/kg), or was attenuated by the 5-HT1A, 5-HT2 and dopamine receptor antagonist spiperone (3 mg/kg, but not 0.3 or 1 mg/kg). On the other hand, the 5-HT1A, 5-HT1B andβ adrenoceptor antagonists pindolol (2 mg/kg) and cyanopindolol (2 mg/kg), the 5-HT1A receptor agonist/antagonist ipsapirone (10 and 35 mg/kg) and haloperidol (0.25 and 0.5 mg/kg) showed a tendency towards enhancing the TFMPP- orm-CPP-induced hyperthermia. The 5-HT1A and α1-adrenoceptor antagonist NAN-190 (1–4 mg/kg), the 5-HT3 antagonists tropisetron (0.01–1 mg/kg) and zacopride (0.5 and 1 mg/kg), theβ-blockers betaxolol (8 mg/kg) and ICI 118, 551 (8 mg/kg), which have no affinity for 5-HT receptors and prazosin (1 mg/kg), did not affect the hyperthermic effect of TFMPP orm-CPP. The hyperthermias studied were not modified, in animals with 5-HT lesion produced byp-chloroamphetamine (PCA) either. All the drugs used as putative receptor antagonists, as well as PCA, did not change or decreased (ipsapirone) the body temperature in heat-adapted rats. The obtained results suggest that the hyperthermia induced by TFMPP orm-CPP is mediated by 5-HT2, and maybe also by 5-HT1c receptors — those which are located postsynaptically.

Key words

Hyperthermia TFMPP m-CPP 5-HT-receptor antagonists 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Auerbach SB, Kamalakannan N, Rutter JJ (1990) TFMPP and RU24969 enhance serotonin release from rat hippocampus 190:51–57Google Scholar
  2. Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylecharane EJ, Richardson BP, Saxena PR (1986) Proposal for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25:563–576Google Scholar
  3. Chojnacka-Wójcik E, Tatarczyńska E, Gołembiowska K, Przegaliński E (1991) Involvement of 5-HT1A receptors in the antidepressant-like activity of gepirone in the forced swimming test in rats. Neuropharmacology 30:711–717Google Scholar
  4. Conn PJ, Sanders-Bush E (1987) Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT2 and 5-HT1C) receptors. J Pharmacol Exp Ther 242:552–557Google Scholar
  5. Dumuis A, Bouheal R, Sebben M, Cory R, Bockaert J (1988) A non-classical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. Mol Pharmacol 34:880–887Google Scholar
  6. Engel G, Gothert M, Hoyer D, Schlicker E, Hillenbrand K (1986) Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites. Naunyn-Schmiedeberg's Arch Pharmacol 332:1–7Google Scholar
  7. Glennon RA, Naiman NA, Pierson ME, Titeler M, Lyon RA, Weisberg E (1988) NAN-190: an arylpiperazine analog that antagonizes the stimulus effects of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT). Eur J Pharmacol 154:339–341Google Scholar
  8. Gudelsky GA, Koenig JI, Meltzer HY) (1986 Thermoregulatory responses to serotonin (5-HT) stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors. Neuropharmacology 25:1307–1313Google Scholar
  9. Heuring RE, Peroutka SJ (1987) Characterization of a novel3H-5-hydroxytryptamine binding site subtype in bovine brain membranes. J Neurosci 7:894–903Google Scholar
  10. Hjorth S, Carlsson A (1986) Is pindolol a mixed agonist-antagonist at central serotonin (5-HT) receptors? Eur J Pharmacol 129:131–138Google Scholar
  11. Hjorth S, Sharp T (1990) Mixed agonist/antagonist properties of NAN-190 at 5-HT1A receptors: behavioural and in vivo brain microdialysis studies. Life Sci 46:955–963Google Scholar
  12. Hoyer D (1988) Functional correlates of serotonin 5-HT1 recognition sites. J Recept Res 8:59–81Google Scholar
  13. Hoyer D (1989) 5-Hydroxytryptamine receptors and effector coupling mechanisms in peripheral tissues. In: Fozard JR (ed) The peripheral action of 5-hydroxytryptamine. Oxford University Press, Oxford, pp 72–99Google Scholar
  14. Hoyer D, Engel G, Kalkman HO (1985) Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes. Radioligand binding studies with [3H] 5-HT, [3H] 8-OH-DPAT, (−)[125I] iodocyanopindolol, [3H] mesulergine and [3H] ketanserin. Eur J Pharmacol 118:13–23Google Scholar
  15. Kennet GA, Curzon G (1988) Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors. Br J Pharmacol 94:137–147Google Scholar
  16. Kłodzińska A, Jaros T, Chojnacka-Wójcik E, Maj J (1989) Exploratory hypoactivity induced bym-trifluoromethylphenylpiperazine (TFMPP) andm-chlorophenylpiperazine (m-CPP). J Neural Transm 1:207–218Google Scholar
  17. Korstanje C, Sprenkels R, Doods HN, Hugtenburg JG, Boddeke E, Batink HD, Thoolen MJMC, Van Zwieten PA (1986) Characterization of flufylline, fluprofylline, ritanserin, butanserin and R 56413 with respect to in-vivo α1-, α2- and 5-HT2-receptor antagonism and in-vitro α1-, α2- and 5-HT2-receptors: comparison with ketanserin. J Pharm Pharmacol 38:374–379Google Scholar
  18. Leysen JE (1990) Gaps and peculiarities in 5-HT2 receptor studies. Neuropsychopharmacology 3:361–369Google Scholar
  19. Maj J, Lewandowska A (1980) Central serotoninmimetic action of phenylpiperazines. Pol J Pharmacol Pharm 32:495–504Google Scholar
  20. Maj J, Baran L, Bigajska K, Rogóż Z, Skuza G (1978) The influence of neuroleptics on the behavioural effect of 5-hydroxytryptophan. Pol J Pharmacol Pharm 30:431–440Google Scholar
  21. Maj J, Chojnacka-Wójcik E, Tatarczyńska E, Kłodzińska A (1987) Central action of ipsapirone, a new anxiolytic drug, on serotoninergic, noradrenergic and dopaminergic functions. J Neural Transm 70:1–17Google Scholar
  22. Maj J, Chojnacka-Wójcik E, Kłodzińska A, Dereń A, Moryl E (1988) Hypothermia induced by m-trifluoromethylphenylpiperazine orm-chlorophenylpiperazine: an effect mediated by 5-HT1B receptors. J Neural Transm 73:43–55Google Scholar
  23. Maura G, Ulivi M, Raiteri M (1987) (−)-Propranolol and (±)-cyanopindolol are mixed agonists-antagonists at serotonin auto receptors in the hippocampus of the rat brain. Neuropharmacology 26:713–717Google Scholar
  24. Middlemiss DN, Fozard JR (1983) 8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of 5-HT1 recognition sites. Eur J Pharmacol 90:151–153Google Scholar
  25. Pawłowski L (1984) Amitryptyline and femoxetine, but not clomipramine or citalopram, antagonize hyperthermia induced by directly acting 5-hydroxytryptamine-like drugs in heat adapted rats. J Pharm Pharmacol 36:197–199Google Scholar
  26. Pedigo NW, Yamamura HI, Nelson DL (1981) Discrimination of multiple3H-5-hydroxytryptamine binding site by the neuroleptic spiperone in the rat brain. J Neurochem 36:220–226Google Scholar
  27. Pettibone DJ, Williams M (1984) Serotonin-releasing effects of substituted piperazines in vitro. Biochem Pharmacol 33:1531–1535Google Scholar
  28. Przegaliński E, Ismaiel AM, Chojnacka-Wójcik E, Budziszewska B, Tatarczyńska E, Błaszczyńska E (1990) The behavioural, but not the hypothermic or corticosterone, response to 8-hydroxy-2-(di-n-propylamino) tetralin, is antagonized by NAN-190 in the rat. Neuropharmacology 29:521–526Google Scholar
  29. Richardson BP, Engel G, Donatsch P, Stadler PA (1985) Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 316:126–131Google Scholar
  30. Sahin-Erdemli I, Schoeffter P, Hoyer D (1991) Competitive antagonism by recognised 5-HT2 receptor antagonists at 5-HT1C in pig choroid plexus. Naunyn-Schmiedeberg's Arch Pharmacol 344:137–142Google Scholar
  31. Sanders-Bush E, Breeding M (1988) Putative selective 5-HT2 antagonists block serotonin 5-HT1C receptors in the choroid plexus. J Pharmacol Exp Ther 247:169–173Google Scholar
  32. Sheldon PW, Aghajanian GK (1991) Excitatory responses to serotonin (5-HT) in neurons of the rat piriform cortex: evidence for mediation by 5-HT1C receptors in pyramidal cells and 5-HT2 receptors in interneurons. Synapse 9:208–218Google Scholar
  33. Sills MA, Wolfe PP, Frazer A (1984) Determination of selective and nonselective compounds for the 5-HT1A and 5-HT1B receptor subtypes in rat frontal cortex. J Pharmacol Exp Ther 231:480–487Google Scholar
  34. Simansky KJ, Schechter LE (1988) Properties of some 1-arylpiperazines as antagonists of stereotyped behaviors mediated by central serotonergic receptors in rodents. J Pharmacol Exp Ther 247:1073–1081Google Scholar
  35. Smith LM, Peroutka SJ (1986) Differential effects of 5-hydroxytryptamine1A selective drugs on the 5-HT behavioral syndrome. Pharmacol Biochem Behav 24:1513–1519Google Scholar
  36. Smith WW, Sancilio LF, Owera-Atepo JB, Naylor RJ, Lambert L (1988) Zacopride, a potent 5-HT3 antagonist. J Pharm Pharmacol 40:301–302Google Scholar
  37. Tricklebank MD, Forler C, Fozard JR (1984) The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)-tetralin in the rat. Eur J Pharmacol 106:271–282Google Scholar
  38. Tricklebank MD, Forler C, Middlemiss DN, Fozard JR (1985) Subtypes of the 5-HT receptor mediating the behavioural responses to 5-methoxy-N, N-dimethyltryptamine in the rat. Eur J Pharmacol 117:15–24Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • A. Kłodzińska
    • 1
  • E. Chojnacka-Wójcik
    • 1
  1. 1.Institute of PharmacologyPolish Academy of SciencesKrakówPoland

Personalised recommendations